Krystal Biotech Inc (KRYS NASDAQ) stock market data APIs
$330.5915
3.52(1.1%)
as of October 15, 2026
Try our APIs with
free plan!
Krystal Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Prev. Close
330.5915
Open
334.1136
High
336.3492
Low
325.386
52 wk Range
183.03-382.535
Market Cap
9 940 M
P/E Ratio
40.854
Shares Outstanding
29 599 K
Revenue
440 M
EPS
1.79
Beta
0.498
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Krystal Biotech Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Krystal Biotech Inc data using free add-ons & libraries
Get Krystal Biotech Inc Fundamental Data
Krystal Biotech Inc Fundamental data includes:
- Net Revenue: 440 M
- EBITDA: 199 M
- Earnings Per Share: 8
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-03
- EPS/Forecast: 1.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Krystal Biotech Inc News
New
What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders
Krystal Biotech's VYJUVEK gene therapy for dystrophic epidermolysis bullosa has already delivered strong commercial traction, generating high revenue and robust gross margins in chronic use. The thera...
Why Krystal Biotech (KRYS) Is Drawing Fresh Attention
Krystal Biotech (KRYS) is drawing fresh attention after news that its VYJUVEK gene therapy for dystrophic epidermolysis bullosa has gained commercial traction, supported by high revenue, strong gross ...
Krystal Biotech (KRYS) Stock Looks Overvalued After A 7x Run
Krystal Biotech has produced a very large 5 year share price gain, which naturally puts the focus on whether that move is supported by the business it has built. With the stock now trading around US$3...
Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?
Krystal Biotech, Inc. (NASDAQ:KRYS) has something most biotech companies spend years trying to achieve: a drug that works, is approved, and is already generating meaningful revenue. VYJUVEK, a gene th...
Get Krystal Biotech Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.